<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>URO-L- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate tablet </strong><br>Method Pharmaceuticals, LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>URO-L Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx Only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Uro-L Tablets for oral administration. </p>
<p>Each tablet contains: <br>Methenamine
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	81 mg<br>Sodium Phosphate Monobasic   
		     
	40.8 mg<br>Phenyl Salicylate
		     
	
		     
	
		     
	
		     
	      32.4 mg<br>Methylene Blue
		     
	
		     
	
		     
	
		     
	        10.8 mg<br>Hyoscyamine Sulfate
		     
	
		     
	
		     
	      0.12 mg</p>
<p>Inactive ingredients: Lactose, Polyethylene Glycol, Crospovidone, Magnesium Stearate, Colloidal Silicon Dioxide, FD&amp;C Blue # 1.</p>
<p>METHENAMINE. [100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1 <span class="Sup">3,7</span>] decane; hexamethylenetetramine; HMT; HMTA; hexamine; 1,3,5,7-tetraazaadamantane hexamethylenemine; Uritone; Urotropin. C<span class="Sub">6</span>H<span class="Sub">12</span>N<span class="Sub">4</span>; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine (hexamethylenetetramine) exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water, soluble in alcohol and in chloroform.</p>
<p>SODIUM PHOSPHATE MONOBASIC. [7558-80-7] Phosphoric acid sodium salt (1:1); Sodium biphosphate; sodium dihydrogen phosphate; acid sodium phosphate; monosodium orthophosphate; primary sodium phosphate; H<span class="Sub">2</span>NaO<span class="Sub">4</span>P; mol wt 119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%. Monohydrate, white, odorless slightly deliquesce crystals or granules. At 100° C loses all its water; when ignited it converts to metaphosphate. It is freely soluble in water and practically insoluble in alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous solution at 25° C: 4.5.</p>
<p>PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C<span class="Sub">13</span>H<span class="Sub">10</span>O<span class="Sub">3</span>; mol wt 214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus oxy-chloride on a mixture of phenol and salicylic acid. Phenyl Salicylate exists as white crystals with a melting point of 41°-43° C. It is very slightly soluble in water and freely soluble in alcohol.</p>
<p>METHYLENE BLUE. [61-73-4] 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride; C.I. Basic Blue 9; methylthioninium chloride; tetramethylthionine chloride; 3,7-bis(dimethylamino) phenazathionium chloride. C<span class="Sub">16</span>H<span class="Sub">18</span>ClN<span class="Sub">3</span>S; mol wt 319.85, C 60.08%, H 5.67%, Cl 11.08%, N 13.14%, S 10.03%. Methylene Blue (Methylthionine chloride) exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.</p>
<p>HYOSCYAMINE SULFATE. [620-61-1] [3(S)-endo]-α-(Hydroxymethyl)-benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester sulfate(2:1)(salt); 1αH,5αH-tropan-3α-ol(-)-tropate (ester) sulfate(2:1)(salt); 3α-tropanyl S-(-)-tropate; I-tropic acid ester with tropine; I-tropine tropate. C<span class="Sub">34</span>H<span class="Sub">48</span>N<span class="Sub">2</span>O<span class="Sub">10</span>S. Hyoscyamine Sulfate is an alkaloid of belladonna. Exists as a white crystalline powder. Its solutions are alkaline to litmus. Affected by light, it is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70 to 90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding - some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at a pH greater than 6.8.</p>
<p>SODIUM PHOSPHATE MONOBASIC an acidifier, helps to maintain an acid pH in the urine necessary for the degradation of methenamine.</p>
<p>PHENYL SALICYLATE releases salicylate, a mild analgesic for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed by the gastrointestinal tract and is rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged.</p>
<p>HYOSCYAMINE SULFATE is a parasympatholytic drug which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout the body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Protein binding for hyoscyamine sulfate is moderate and biotransformation is hepatic.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Uro-L Tablets is indicated for the treatment of symptoms of irritative voiding. </p>
<p>Indicated for the relief of local symptoms, such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, hypermotility, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, which accompany lower <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
<p>Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Uro-L Tablets is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, coronary heart disease, and <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span>); gastrointestinal tract obstructive disease; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may be precipitated in <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (such as <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Do not exceed recommended dosage. If rapid pulse, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> occurs, discontinue use immediately.</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. </p>
<p>IN CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Cross sensitivity and/or related problems:<br>Patients intolerant of other belladonna alkaloids or other salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.1"></a><p></p>
<h2>Pregnancy/Reproduction (FDA Pregnancy Category C): </h2>
<p class="First">Hyoscyamine and methenamine cross the placenta. Studies have not been done in either animals or humans. It is not known whether Uro-L Tablets tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Uro-L Tablets tablets should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.2"></a><p></p>
<h2>Nursing mothers: </h2>
<p class="First">Methenamine and traces of hyoscyamine are excreted in breast milk. Caution should be exercised when Uro-L Tablets tablets are administered to a nursing mother.</p>
<p>Prolonged use: <br>There have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.3"></a><p></p>
<h2>Pediatric: </h2>
<p class="First">Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.4"></a><p></p>
<h2>Geriatric: </h2>
<p class="First">Use with caution in elderly patients as they may respond to the usual doses of the belladonna alkaloids with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Cardiovascular - rapid pulse, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p>Central Nervous System - <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></p>
<p>Respiratory - <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or troubled breathing</p>
<p>Genitourinary - difficult micturition, acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p>Gastrointestinal - <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, severe <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or trouble breathing.</p>
<p>This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped.</p>
<p>Call your doctor or physician for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Method Pharmaceuticals, LLC at (877) 250-3427. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-9"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">As a result of hyoscyamine's effects on gastrointestinal motility and gastric emptying, absorption of other oral medications may be decreased during concurrent use with this combination medication.</p>
<p>Urinary alkalizers and thiazide diuretics: May cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde.</p>
<p>Antimuscarinics: Concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications.</p>
<p>Antacids/antidiarrheals: Concurrent use may reduce absorption of hyoscyamine resulting in decreased therapeutic effectiveness. Concurrent use with antacids may cause urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. Doses of these medications should be spaced 1 hour apart from doses of hyoscyamine.</p>
<p>Antimyasthenics: Concurrent use with hyoscyamine may further reduce intestinal motility, therefore, caution is recommended.</p>
<p>Ketoconazole and hyoscyamine may cause increased gastrointestinal pH.</p>
<p>Concurrent administration with hyoscyamine may result in marked reduction in the absorption of ketoconazole. Patients should be advised to take this combination at least 2 hours after ketoconazole.</p>
<p>Monoamine oxidase (MAO) inhibitors: Concurrent use with hyoscyamine may intensify antimuscarinic side effects.</p>
<p>Opioid (narcotic) analgesics may result in increased risk of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p>Sulfonamides: These drugs may precipitate with formaldehyde in the urine increasing the danger of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
<p>Patients should be advised that the urine and/or stools may become blue to blue-green as a result of the excretion of methylene blue.</p>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9.1"></a><p></p>
<h2>Drug Abuse And <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </h2>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on the use of Uro-L Tablets has not been reported and due to the nature of its ingredients, abuse of Uro-L Tablets is not expected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children) repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. </p>
<p>Administration of small doses of diazepam to control <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Artificial respiration with oxygen if needed for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. </p>
<p>Adequate hydration. </p>
<p>Symptomatic treatment as necessary.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, contact the poison control center at 1-800-222-1222, or your local emergency room immediately.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Adults: One tablet orally 4 times per day followed by liberal fluid intake.</p>
<p>Pediatric: Dosage must be individualized by physician for older children. Not recommended for use in children six years of age or younger.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Uro-L Tablets are blue speckled tablets imprinted with 210 on one side and plain on the other, available in bottles of 90 tablets, (NDC: 58657-457-90).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store in a cool, dry place at controlled room temperature 15° to 30°C (59° to 86°F).  Keep container tightly closed. Protect from moisture and direct sunlight.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP/NF with a child resistant closure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-14"></a><p></p>
<h1>WARNING: </h1>
<p class="First">Keep this and all drugs out of reach of children. </p>
<p>Rx Only</p>
<p>Manufactured for:<br>Method Pharmaceuticals, LLC<br>Arlington, TX 76006<br>www.methodpharm.com</p>
<p>Rev. 10/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">NDC</span><span class="Bold"> 586</span><span class="Bold">57-457-90</span><br><span class="Bold">Uro</span><span class="Bold">-L Tablets</span><span class="Bold"><br>Rx Only</span><span class="Bold"><br>90 Tablets</span></p>
<p><br><img alt="PRINCIPAL DISPLAY PANEL
NDC 58657-457-90
Uro-L Tablets
Rx Only
90 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=263ed7eb-a390-4a26-9985-16ac883f4bfc&amp;name=uro-l-tablets-01.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>URO-L 		
					</strong><br><span class="contentTableReg">methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58657-457</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHENAMINE</strong> (METHENAMINE) </td>
<td class="formItem">METHENAMINE</td>
<td class="formItem">81 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</strong> (SODIUM CATION) </td>
<td class="formItem">SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</td>
<td class="formItem">40.8 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENYL SALICYLATE</strong> (PHENYL SALICYLATE) </td>
<td class="formItem">PHENYL SALICYLATE</td>
<td class="formItem">32.4 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METHYLENE BLUE</strong> (METHYLENE BLUE CATION) </td>
<td class="formItem">METHYLENE BLUE</td>
<td class="formItem">10.8 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.12 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Blue, speckled) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oval, Capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">210</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58657-457-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">12/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Method Pharmaceuticals, LLC
							(060216698)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>103b8f01-22a0-4c0c-b547-4fa2ed93e4da</div>
<div>Set id: 263ed7eb-a390-4a26-9985-16ac883f4bfc</div>
<div>Version: 1</div>
<div>Effective Time: 20141203</div>
</div>
</div> <div class="DistributorName">Method Pharmaceuticals, LLC</div></p>
</body></html>
